No Data
CIRC (01763): The clinical trial notification for a Class 1 Innovative Drug developed by Atomical for melanoma imaging has been approved.
CIRC (01763) announced that on December 24, 2024, its subsidiary Atomic Gaoke Co., ...
CIRC (01763.HK): The ESG case has won the "2024 Excellent Case of ESG in Chinese Enterprises."
On December 23, Gelonghui reported that CIRC (01763.HK) announced that recently, the 2024 Corporate ESG Sustainable Development Conference, jointly organized by the China Enterprise Reform and Development Research Association and Banmiu Magazine, was successfully held in Peking. The company's ESG case "Focusing on Constructing a New Pattern of Green and High-Quality Development in the Nuclear Technology Application Industry" stood out from over 700 submitted cases, winning the title of "2024 Outstanding ESG Case for Chinese Enterprises." The company will continue to lead future health with technological innovation, constantly improve the layout of research and development for radioactive Pharmaceuticals and nuclear Medical equipment, increase efforts on "bottleneck" technology breakthroughs, and bravely shoulder the responsibility of "Health China."
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
CIRC (01763.HK) has established a joint venture company, Gansu Hongye.
On December 16, Glonghui reported that CIRC (01763.HK) announced that on December 16, 2024, the company's subsidiary, Qualcomm, signed an "Investment Agreement" with the 404 Company and Other investment entities to establish the joint venture Gansu Hongye. According to the "Investment Agreement", the registered capital of Gansu Hongye is 95 million RMB, of which the 404 Company will contribute 57 million RMB in MMF, and the company's subsidiary Qualcomm will contribute 9.5 million RMB in MMF. After the establishment of Gansu Hongye, the 404 Company and the company's subsidiary Qualcomm will hold 60% and respectively.
Express News | China Isotope & Radiation Corp - Registered Capital of Gansu Hongye Is RMB95 Mln
Express News | China Isotope & Radiation Corp - Entering Into Investment Agreement on Establishment of Joint Venture Co
